Oxford BioMedica announces a £2 million two-year collaboration co-funded by Innovate UK

Agreement is to explore a next generation gene and cell therapy manufacturing platform for clinical and commercial applications

Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, has announced it has agreed, as lead partner, to enter into a collaboration agreement with a consortium of partners, including the Cell and Gene Therapy Catapult, Stratophase Ltd and Synthace Ltd. The agreement is a two-year £2 million collaboration project focused on gene and cell therapy manufacturing, co-funded by the UK’s innovation agency, Innovate UK.

Discover who we are